Treatment outcomes of conventional or high-dose ranibizumab for vascularized pigment epithelial detachment based on lesion subtypes
A post hoc study was conducted to compare visual and anatomic outcomes of vascularized serous pigment epithelial detachment (Group 1) with fibrovascular pigment epithelial detachment (Group 2) due to age-related macular degeneration treated with either 0.5 or 2.0 mg ranibizumab injections. A prospec...
Saved in:
| Published in: | European journal of ophthalmology Vol. 28; no. 6; p. 677 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.11.2018
|
| Subjects: | |
| ISSN: | 1724-6016, 1724-6016 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | A post hoc study was conducted to compare visual and anatomic outcomes of vascularized serous pigment epithelial detachment (Group 1) with fibrovascular pigment epithelial detachment (Group 2) due to age-related macular degeneration treated with either 0.5 or 2.0 mg ranibizumab injections.
A prospective, randomized trial was performed with the following regimens for 12 months: (1) 0.5 mg monthly, (2) 0.5 mg monthly for 4 months followed by pro re nata injections, (3) 2.0 mg monthly, and (4) 2.0 mg monthly for 4 months followed by pro re nata injections. Primary measure was best-corrected standardized vision. Secondary measures included central subfield, thickness surface area A
, greatest linear diameter, heights of pigment epithelial detachment and choroidal neovascularization (CNV), subretinal fluid, cystoid macular edema, and adverse events.
For 36 eyes (8 in Group 1 and 28 in Group 2), follow-up time was 12 months. There were no differences in baseline features between groups except for pigment epithelial detachment A
(Group 2 > Group 1). Two-way analysis of variance showed comparable improvements in anatomic and vision outcomes. Three-way analysis of variance also showed similar responses for both lesion subtypes with high-dose treatment. There was a trend toward greater pigment epithelial detachment resolution in Group 1 eyes. There were no differences in retinochoroidal angiomatous proliferation (Type-3 CNV) and cataracts between groups, although greater percentages of eyes in Group 1 developed retinal pigment epithelial tears (25% vs 10.7%).
There were no differences in vision and anatomic outcomes between lesion subtypes, and similarly, more rapid responses to high-dose than conventional-dose ranibizumab occurred for eyes with both lesion subtypes. More retinal pigment epithelial tears may develop in eyes with vascularized serous pigment epithelial detachment. |
|---|---|
| AbstractList | A post hoc study was conducted to compare visual and anatomic outcomes of vascularized serous pigment epithelial detachment (Group 1) with fibrovascular pigment epithelial detachment (Group 2) due to age-related macular degeneration treated with either 0.5 or 2.0 mg ranibizumab injections.INTRODUCTION:A post hoc study was conducted to compare visual and anatomic outcomes of vascularized serous pigment epithelial detachment (Group 1) with fibrovascular pigment epithelial detachment (Group 2) due to age-related macular degeneration treated with either 0.5 or 2.0 mg ranibizumab injections.A prospective, randomized trial was performed with the following regimens for 12 months: (1) 0.5 mg monthly, (2) 0.5 mg monthly for 4 months followed by pro re nata injections, (3) 2.0 mg monthly, and (4) 2.0 mg monthly for 4 months followed by pro re nata injections. Primary measure was best-corrected standardized vision. Secondary measures included central subfield, thickness surface area A2, greatest linear diameter, heights of pigment epithelial detachment and choroidal neovascularization (CNV), subretinal fluid, cystoid macular edema, and adverse events.METHODS:A prospective, randomized trial was performed with the following regimens for 12 months: (1) 0.5 mg monthly, (2) 0.5 mg monthly for 4 months followed by pro re nata injections, (3) 2.0 mg monthly, and (4) 2.0 mg monthly for 4 months followed by pro re nata injections. Primary measure was best-corrected standardized vision. Secondary measures included central subfield, thickness surface area A2, greatest linear diameter, heights of pigment epithelial detachment and choroidal neovascularization (CNV), subretinal fluid, cystoid macular edema, and adverse events.For 36 eyes (8 in Group 1 and 28 in Group 2), follow-up time was 12 months. There were no differences in baseline features between groups except for pigment epithelial detachment A2 (Group 2 > Group 1). Two-way analysis of variance showed comparable improvements in anatomic and vision outcomes. Three-way analysis of variance also showed similar responses for both lesion subtypes with high-dose treatment. There was a trend toward greater pigment epithelial detachment resolution in Group 1 eyes. There were no differences in retinochoroidal angiomatous proliferation (Type-3 CNV) and cataracts between groups, although greater percentages of eyes in Group 1 developed retinal pigment epithelial tears (25% vs 10.7%).RESULTS:For 36 eyes (8 in Group 1 and 28 in Group 2), follow-up time was 12 months. There were no differences in baseline features between groups except for pigment epithelial detachment A2 (Group 2 > Group 1). Two-way analysis of variance showed comparable improvements in anatomic and vision outcomes. Three-way analysis of variance also showed similar responses for both lesion subtypes with high-dose treatment. There was a trend toward greater pigment epithelial detachment resolution in Group 1 eyes. There were no differences in retinochoroidal angiomatous proliferation (Type-3 CNV) and cataracts between groups, although greater percentages of eyes in Group 1 developed retinal pigment epithelial tears (25% vs 10.7%).There were no differences in vision and anatomic outcomes between lesion subtypes, and similarly, more rapid responses to high-dose than conventional-dose ranibizumab occurred for eyes with both lesion subtypes. More retinal pigment epithelial tears may develop in eyes with vascularized serous pigment epithelial detachment.CONCLUSION:There were no differences in vision and anatomic outcomes between lesion subtypes, and similarly, more rapid responses to high-dose than conventional-dose ranibizumab occurred for eyes with both lesion subtypes. More retinal pigment epithelial tears may develop in eyes with vascularized serous pigment epithelial detachment. A post hoc study was conducted to compare visual and anatomic outcomes of vascularized serous pigment epithelial detachment (Group 1) with fibrovascular pigment epithelial detachment (Group 2) due to age-related macular degeneration treated with either 0.5 or 2.0 mg ranibizumab injections. A prospective, randomized trial was performed with the following regimens for 12 months: (1) 0.5 mg monthly, (2) 0.5 mg monthly for 4 months followed by pro re nata injections, (3) 2.0 mg monthly, and (4) 2.0 mg monthly for 4 months followed by pro re nata injections. Primary measure was best-corrected standardized vision. Secondary measures included central subfield, thickness surface area A , greatest linear diameter, heights of pigment epithelial detachment and choroidal neovascularization (CNV), subretinal fluid, cystoid macular edema, and adverse events. For 36 eyes (8 in Group 1 and 28 in Group 2), follow-up time was 12 months. There were no differences in baseline features between groups except for pigment epithelial detachment A (Group 2 > Group 1). Two-way analysis of variance showed comparable improvements in anatomic and vision outcomes. Three-way analysis of variance also showed similar responses for both lesion subtypes with high-dose treatment. There was a trend toward greater pigment epithelial detachment resolution in Group 1 eyes. There were no differences in retinochoroidal angiomatous proliferation (Type-3 CNV) and cataracts between groups, although greater percentages of eyes in Group 1 developed retinal pigment epithelial tears (25% vs 10.7%). There were no differences in vision and anatomic outcomes between lesion subtypes, and similarly, more rapid responses to high-dose than conventional-dose ranibizumab occurred for eyes with both lesion subtypes. More retinal pigment epithelial tears may develop in eyes with vascularized serous pigment epithelial detachment. |
| Author | Chan, Clement K Abraham, Prema Sarraf, David |
| Author_xml | – sequence: 1 givenname: Clement K surname: Chan fullname: Chan, Clement K organization: 3 Department of Ophthalmology, Loma Linda University, Loma Linda, CA, USA – sequence: 2 givenname: David surname: Sarraf fullname: Sarraf, David organization: 4 Jules Stein Eye Institute/UCLA, Los Angeles, CA, USA – sequence: 3 givenname: Prema surname: Abraham fullname: Abraham, Prema organization: 5 Black Hills Regional Eye Institute, Rapid City, SD, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29575941$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkD1PwzAQhi1UBKWwMyGPLAF_xsmIKr6kSixljhzn0lhK7BA7ldqVP05aisR0r9577hnuCs2cd4DQLSUPlCr1SCkjqWKHLBTh4gzNqWIiSQlNZ__yBbpkuVQyF3SOvtcD6NiBi9iP0fgOAvY1Nt5tp856p1vsB9zYTZNUPgAetLOl3Y-dLnE9bbY6mLHVg91DhXu7Oaqgt7GB1k7HFURtmmNb6jAx3uEWwmTGYSzjrodwjc5r3Qa4Oc0F-nx5Xi_fktXH6_vyaZUYzlVMuNSMM5NJoiUVWnNTQwZcgoGcSZNXGRBaK5OVwoiqUoaVEyZoboShVGZsge5_vf3gv0YIsehsMNC22oEfQ8EIzdJUcHZA707oWHZQFf1gOz3sir_HsR_ko3Jc |
| CitedBy_id | crossref_primary_10_3390_jpm14101041 crossref_primary_10_1177_11206721211006572 crossref_primary_10_1016_j_survophthal_2020_05_003 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1177/1120672117747034 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 1724-6016 |
| ExternalDocumentID | 29575941 |
| Genre | Randomized Controlled Trial Journal Article |
| GroupedDBID | CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c337t-35a232c850a514aa3cfe8e35ece925c9d8e01f7c8b4c4dd7c2b14a419c4c11582 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 2 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000449834800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1724-6016 |
| IngestDate | Fri Jul 11 10:30:05 EDT 2025 Thu Jan 02 23:04:05 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | retinal pigment epithelial tears vascularized pigment epithelial detachment Fibrovascular pigment epithelial detachment vascularized serous pigment epithelial detachment |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c337t-35a232c850a514aa3cfe8e35ece925c9d8e01f7c8b4c4dd7c2b14a419c4c11582 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 29575941 |
| PQID | 2018664328 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2018664328 pubmed_primary_29575941 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-Nov 20181101 |
| PublicationDateYYYYMMDD | 2018-11-01 |
| PublicationDate_xml | – month: 11 year: 2018 text: 2018-Nov |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | European journal of ophthalmology |
| PublicationTitleAlternate | Eur J Ophthalmol |
| PublicationYear | 2018 |
| Score | 2.1743102 |
| Snippet | A post hoc study was conducted to compare visual and anatomic outcomes of vascularized serous pigment epithelial detachment (Group 1) with fibrovascular... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 677 |
| SubjectTerms | Aged Aged, 80 and over Analysis of Variance Angiogenesis Inhibitors - therapeutic use Choroidal Neovascularization - drug therapy Choroidal Neovascularization - pathology Contrast Sensitivity - physiology Female Humans Intravitreal Injections Male Middle Aged Prospective Studies Ranibizumab - therapeutic use Retinal Detachment - drug therapy Retinal Detachment - pathology Retinal Detachment - physiopathology Retinal Pigment Epithelium - pathology Tomography, Optical Coherence Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology |
| Title | Treatment outcomes of conventional or high-dose ranibizumab for vascularized pigment epithelial detachment based on lesion subtypes |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29575941 https://www.proquest.com/docview/2018664328 |
| Volume | 28 |
| WOSCitedRecordID | wos000449834800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV2_a9wwFBZpL0OXtCFpe2kTVOgqcpZkW55CKA1ZetxwgduM_PTUGlL7Gt9lyJp_PO_5bNKlUMhiZGMJI33S-_x-CvG1wMr7mGcqAMyUjS5RDojIBchIePk0Md72xSby-dytVsViULh1g1vleCb2B3VogXXk9JPOqdms0e5i_Udx1Si2rg4lNF6JiSEqw6jOV330W66t4kwjz5bJc2IWbHfktiWc239zyl62XL196Ve9EwcDq5SXOxgcij1sjsTjcnQil-12Q-NhJ9so__Yzl-2d5ITFKrQdShJbdVU_bH_7ShKXlaOXav2AQa7rn_1QuOYojluCrWT3U_jVP2VhGGTbyFtk9ZvsthUrd7tjcXP1ffntWg01FxQYk2-UST1xLHDpjNbJem8gokOTImChUyiCw1kSc3CVBRtCDrqi12xSgAUil06_F6-btsGPQlpErT31A5tazJzLIkQNmdOxMK7Kp-LLOKclYZoNFb7BdtuVz7M6FR92C1Oud8k3Sl1wSVGbnPxH70_iDd_sQgc_i0mkHY2nYh_uN3V3d9aDha7zxY8n9lPO4Q |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+outcomes+of+conventional+or+high-dose+ranibizumab+for+vascularized+pigment+epithelial+detachment+based+on+lesion+subtypes&rft.jtitle=European+journal+of+ophthalmology&rft.au=Chan%2C+Clement+K&rft.au=Sarraf%2C+David&rft.au=Abraham%2C+Prema&rft.date=2018-11-01&rft.issn=1724-6016&rft.eissn=1724-6016&rft.volume=28&rft.issue=6&rft.spage=677&rft_id=info:doi/10.1177%2F1120672117747034&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1724-6016&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1724-6016&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1724-6016&client=summon |